Text Size

A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00415428
First received: December 20, 2006
Last updated: September 18, 2009
Last verified: September 2009
History of Changes
  Purpose

The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.


Condition Intervention
Heart Diseases
Diabetes Mellitus, Type 2
 Behavioral: Patient adherence to national educational guidelines.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Patient And Physician Alliance -Guideline Education Treatment Optimization

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Pfizer:

Enrollment: 2776
Study Start Date: January 2007
Study Completion Date: September 2008
Groups/Cohorts Assigned Interventions
Not Specified
Not Specified
 Behavioral: Patient adherence to national educational guidelines.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Primary care clinic patients

Criteria

Inclusion Criteria:

  • Subjects had to meet all of the inclusion criteria to be eligible for enrollment into the study. The following subjects qualify for inclusion in the study:
  • Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL) cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned independently of this observational study and for whom baseline values were or became available.
  • Subjects with known CVD diagnosed > or = 6 months before inclusion
  • Previous myocardial infarction
  • Ischemic heart disease (stable and unstable angina pectoris)
  • Ischemic apoplexy
  • Peripheral arterial disease
  • And/Or
  • Subjects with T2D diagnosed > or = 6 months before inclusion
  • At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be <6 months before inclusion.

Exclusion Criteria:

  • Subjects presenting with any of the following were not to be included in the study:
  • Life expectancy of < or = 2 years
  • Unable/unwilling to understand/follow instructions
  • Taking part in a clinical study involving an investigational drug
  • Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00415428

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00415428     History of Changes
Other Study ID Numbers: A2581154
Study First Received: December 20, 2006
Last Updated: September 18, 2009
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Cardiovascular Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2
Heart Diseases
 Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 23, 2013